Facilitating Access Consortium Work Sharing for Biosimilars

Building on the experience of international work sharing initiatives under the Access Consortium, this document outlines key information for industry in filing an international work sharing submission for biosimilars. Access Consortium work sharing offers sponsors:


New drug submissions filed with 2 or more partner regulators for a new biosimilar.

Guidance for Industry

  1. Advance notice: Early interactions with regulators are important for assessing whether work sharing is a feasible option, and for assisting with alignment and planning discussions.
    • If possible, sponsors should provide the Expression of Interest (EOI) form up to 6 months in advance, in particular when seeking a technical pre-submission meeting.
    • Industry is invited to submit an EOI form at least 3 months before the intended filing date.
    • Interested applicants are invited to participate by contacting their regional regulatory authority.
    • Communications via email should include "Access Consortium – Biosimilars Work Sharing" in the subject line.
  2. Coordinated filing: Sponsors are required to file separate applications to each participating regulator within a 2-week window of each other.Footnote 1
  3. Consistency in submission of information provided: The content of submissions across partner regulators should be consistent, with the exception of select nation-specific application requirements that should be noted in the EOI form.

Regulatory Commitments

  1. Predictability and transparency: Sponsors will be informed (typically within 6 weeks) of the potential for work sharing prior to the filing of the dossier. Partner regulators will identify the following: the lead regulator; project milestones; review stream leads; and model of collaboration deemed appropriate for the submission. Regulators will then inform the sponsor on the work sharing approach and the key milestones at the earliest opportunity.
  2. Coordinated approach: Sponsors can expect key communications from regulators according to the project milestones and using the standard communication modes (e.g. clarification requests, announcements of positive decisions or authorizations).
  3. Sovereign processes and decisions: Countries will maintain their sovereign processes and decision-making. For example, national procedures will be followed: i) at the validation/screening stage; ii) at the labelling stage (e.g. indication, PM, container labels) and iii) at the stage of authorization or rejection of market authorization.

Page details

Date modified: